文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

EMT 是人类结肠癌中的主要程序。

EMT is the dominant program in human colon cancer.

机构信息

Merck, Sharp and Dohme, West Point, PA 19486, USA.

出版信息

BMC Med Genomics. 2011 Jan 20;4:9. doi: 10.1186/1755-8794-4-9.


DOI:10.1186/1755-8794-4-9
PMID:21251323
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3032646/
Abstract

BACKGROUND: Colon cancer has been classically described by clinicopathologic features that permit the prediction of outcome only after surgical resection and staging. METHODS: We performed an unsupervised analysis of microarray data from 326 colon cancers to identify the first principal component (PC1) of the most variable set of genes. PC1 deciphered two primary, intrinsic molecular subtypes of colon cancer that predicted disease progression and recurrence. RESULTS: Here we report that the most dominant pattern of intrinsic gene expression in colon cancer (PC1) was tightly correlated (Pearson R = 0.92, P < 10(-135)) with the EMT signature-- both in gene identity and directionality. In a global micro-RNA screen, we further identified the most anti-correlated microRNA with PC1 as MiR200, known to regulate EMT. CONCLUSIONS: These data demonstrate that the biology underpinning the native, molecular classification of human colon cancer--previously thought to be highly heterogeneous-- was clarified through the lens of comprehensive transcriptome analysis.

摘要

背景:结肠癌已被临床病理特征进行了经典描述,这些特征仅在手术切除和分期后才能预测预后。

方法:我们对 326 例结肠癌的基因表达谱芯片数据进行了无监督分析,以确定最具变异性的基因集的第一主成分(PC1)。PC1 解析了两种主要的结肠癌内在分子亚型,可预测疾病进展和复发。

结果:在这里,我们报告在结肠癌中(PC1)最主要的内在基因表达模式与 EMT 特征紧密相关(Pearson R = 0.92,P < 10(-135))-在基因身份和方向性上都是如此。在全局 microRNA 筛选中,我们进一步确定了与 PC1 最反相关的 microRNA 为 MiR200,已知其可调节 EMT。

结论:这些数据表明,通过全面转录组分析的视角,阐明了先前被认为高度异质性的人类结肠癌固有分子分类所依据的生物学基础。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd7d/3032646/55b54ed6fe4e/1755-8794-4-9-4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd7d/3032646/b2ae76d4259d/1755-8794-4-9-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd7d/3032646/b79c7663652f/1755-8794-4-9-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd7d/3032646/f33bb8175f30/1755-8794-4-9-3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd7d/3032646/55b54ed6fe4e/1755-8794-4-9-4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd7d/3032646/b2ae76d4259d/1755-8794-4-9-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd7d/3032646/b79c7663652f/1755-8794-4-9-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd7d/3032646/f33bb8175f30/1755-8794-4-9-3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd7d/3032646/55b54ed6fe4e/1755-8794-4-9-4.jpg

相似文献

[1]
EMT is the dominant program in human colon cancer.

BMC Med Genomics. 2011-1-20

[2]
Wnt3a expression is associated with epithelial-mesenchymal transition and promotes colon cancer progression.

J Exp Clin Cancer Res. 2014-12-11

[3]
Colon cancer at the molecular level--usefulness of epithelial-mesenchymal transition analysis.

Rev Med Chir Soc Med Nat Iasi. 2012

[4]
Integrative multi-omics analysis of a colon cancer cell line with heterogeneous Wnt activity revealed RUNX2 as an epigenetic regulator of EMT.

Oncogene. 2020-6-13

[5]
Targeting TYRO3 inhibits epithelial-mesenchymal transition and increases drug sensitivity in colon cancer.

Oncogene. 2016-5-2

[6]
A Composite Gene Expression Signature Optimizes Prediction of Colorectal Cancer Metastasis and Outcome.

Clin Cancer Res. 2016-2-1

[7]
Ectopic Expression of miR-147 Inhibits Stem Cell Marker and Epithelial-Mesenchymal Transition (EMT)-Related Protein Expression in Colon Cancer Cells.

Oncol Res. 2018-2-9

[8]
A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition.

Clin Cancer Res. 2016-2-1

[9]
HDAC inhibitors induce epithelial-mesenchymal transition in colon carcinoma cells.

Oncol Rep. 2015-5

[10]
miR-22 and miR-214 targeting BCL9L inhibit proliferation, metastasis, and epithelial-mesenchymal transition by down-regulating Wnt signaling in colon cancer.

FASEB J. 2019-1-30

引用本文的文献

[1]
Colorectal cancer heterogeneity co-evolves with tumor architecture to determine disease outcome.

bioRxiv. 2025-8-13

[2]
Personalized risk stratification in colorectal cancer via PIANOS system.

Nat Commun. 2025-7-16

[3]
Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047.

Clin Cancer Res. 2025-9-2

[4]
Colorectal cancer progression to metastasis is associated with dynamic genome-wide biphasic 5-hydroxymethylcytosine accumulation.

BMC Biol. 2025-4-16

[5]
Prognostic markers and molecular pathways in primary colorectal cancer with a high potential of liver metastases: a systems biology approach.

Res Pharm Sci. 2025-2-20

[6]
Thrombospondin 1 Promotes Cytoskeleton Remodeling, Dedifferentiation, and Pulmonary Metastasis through ITGA1 and ITGA6 in Osteosarcoma.

Int J Biol Sci. 2025-2-18

[7]
Identifying distinct prognostic and predictive contributions of tumor epithelium versus tumor microenvironment in colorectal cancer.

BMC Cancer. 2025-3-12

[8]
Effect of prior and first-line immunotherapy on baseline immune biomarkers and modulation of the tumor microenvironment in response to nivolumab and relatlimab combination therapy in patients with melanoma from RELATIVITY-020.

J Immunother Cancer. 2025-2-25

[9]
Real-World Evidence of Bevacizumab and Panitumumab Drug Resistance and Drug Ineffectiveness from EudraVigilance Database.

Cancers (Basel). 2025-2-16

[10]
A novel USP4 inhibitor that suppresses colorectal cancer stemness by promoting β-catenin and Twist1 degradation.

J Transl Med. 2025-1-24

本文引用的文献

[1]
A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors.

BMC Med Genomics. 2010-6-30

[2]
Cancer mortality in Italy, 2003.

Tumori. 2009

[3]
Normal colon epithelium: a dataset for the analysis of gene expression and alternative splicing events in colon disease.

BMC Genomics. 2010-1-4

[4]
Epithelial to mesenchymal transition is impaired in colon cancer cells with microsatellite instability.

Gastroenterology. 2009-12-21

[5]
Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates.

Cancer. 2010-2-1

[6]
Metastasis-Associated Gene Expression Changes Predict Poor Outcomes in Patients with Dukes Stage B and C Colorectal Cancer.

Clin Cancer Res. 2009-12-15

[7]
Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer.

Gastroenterology. 2009-11-13

[8]
Gene expression profiling of primary and metastatic colon cancers identifies a reduced proliferative rate in metastatic tumors.

Clin Exp Metastasis. 2009-11-1

[9]
KLF17 is a negative regulator of epithelial-mesenchymal transition and metastasis in breast cancer.

Nat Cell Biol. 2009-11

[10]
Integrative approach for prioritizing cancer genes in sporadic colon cancer.

Genes Chromosomes Cancer. 2009-11

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索